Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Nu Skin Enterprises (NYSE:NUS – Get Free Report) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Earnings & Valuation
This table compares Dermata Therapeutics and Nu Skin Enterprises”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($4.39) | -0.31 |
| Nu Skin Enterprises | $1.49 billion | 0.16 | $160.20 million | ($4.47) | -1.09 |
Profitability
This table compares Dermata Therapeutics and Nu Skin Enterprises’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -166.66% | -130.13% |
| Nu Skin Enterprises | -15.73% | 6.58% | 3.63% |
Risk and Volatility
Dermata Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Nu Skin Enterprises has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Insider and Institutional Ownership
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Dermata Therapeutics and Nu Skin Enterprises, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Nu Skin Enterprises | 2 | 0 | 0 | 0 | 1.00 |
Summary
Nu Skin Enterprises beats Dermata Therapeutics on 6 of the 10 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
